Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia
Lian Xu(Dana-Farber Cancer Institute), Nicholas Tsakmaklis(Dana-Farber Cancer Institute), Guang Yang(Harvard University), Jiaji G. Chen(Dana-Farber Cancer Institute), Xia Liu(Dana-Farber Cancer Institute), Maria Demos(Dana-Farber Cancer Institute), Amanda Kofides(Dana-Farber Cancer Institute), Christopher J. Patterson(Dana-Farber Cancer Institute), Kirsten Meid(Dana-Farber Cancer Institute), Joshua Gustine(Dana-Farber Cancer Institute), Toni Dubeau(Dana-Farber Cancer Institute), M. Lia Palomba(Memorial Sloan Kettering Cancer Center), Ranjana H. Advani(Stanford Medicine), Jorge J. Castillo(Harvard University), Richard R. Furman(Cornell University), Zachary R. Hunter(Harvard University), Steven P. Treon(Harvard University)
Cited by 138Open Access
Abstract
Key Points BTKCys481 mutations, including multiple mutated variants within individual patients are common in ibrutinib-progressing WM patients. BTKCys481 mutations were associated with mutated CXCR4 in WM patients progressing on ibrutinib.
Related Papers
No related papers found
Powered by citation graph analysis